Is BPC-157 Legal in Washington State?

What Federal Law Actually Says About BPC-157

BPC-157 is not an FDA-approved drug. That single fact shapes every other legal question. Because no New Drug Application (NDA) has been approved for BPC-157, it cannot legally be marketed as a finished pharmaceutical product for human use in the United States. The Federal Food, Drug, and Cosmetic Act (FD&C Act) prohibits introducing an unapproved new drug into interstate commerce for human therapeutic use. [1]

The FDA Bulk Substances List and Category 2

The Drug Quality and Security Act of 2013 (DQSA) created a formal framework for compounding pharmacies operating under Sections 503A and 503B of the FD&C Act. [2] Under that framework, the FDA maintains a list of bulk drug substances that may be used in compounded preparations. Substances the agency has concerns about, but has not yet banned outright, land in "Category 2," which means the FDA has identified a potential safety, effectiveness, or quality concern and is still evaluating the evidence.

The FDA formally placed BPC-157 on the 503A Bulk Substances Nominated List with a Category 2 designation in 2023, citing insufficient evidence of safety and effectiveness for human use. [3] This does not constitute a final rule prohibiting compounding. Until the FDA publishes a final adverse determination in the Federal Register, 503A-registered compounding pharmacies can still technically prepare BPC-157 for individual patients with a valid prescription. The Category 2 placement is a clear regulatory signal: the FDA's position is skeptical, and compounders who continue preparing it carry growing legal and liability risk.

503A vs. 503B: Why the Distinction Matters

A 503A pharmacy compounds for individual patients based on a specific prescription. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and is subject to current Good Manufacturing Practice (cGMP) standards. [4] BPC-157 is not on the 503B "bulks list," which means 503B facilities may not legally compound it at all. The only remaining compounding pathway for human use, while Category 2 status is unresolved, runs through 503A pharmacies.

Washington State Regulatory Framework

Washington State has no law, regulation, or pharmacy board rule that specifically names BPC-157. Searching the Washington Administrative Code (WAC) and the Revised Code of Washington (RCW) returns zero results for "BPC-157" or "body protection compound." State law does not add an additional layer of permission or restriction beyond the federal baseline.

Washington State Pharmacy Quality Assurance Commission

The Washington State Pharmacy Quality Assurance Commission (PQAC) licenses and regulates compounding pharmacies operating inside the state. Washington pharmacies that compound BPC-157 for human use must comply with federal 503A standards and the PQAC's own compounding rules codified in WAC 246-878. Because the PQAC defers to FDA guidance on bulk substance eligibility, the federal Category 2 determination functionally limits what Washington compounders can produce without legal exposure.

Medical Practice Act Considerations

Washington's Uniform Disciplinary Act (RCW 18.130) allows the Medical Quality Assurance Commission to sanction any licensed prescriber who prescribes drugs in a manner inconsistent with the standard of care. Prescribing a peptide with a Category 2 FDA designation, no approved NDA, and limited human clinical trial data may be considered outside the standard of care depending on clinical context. Washington prescribers should document medical necessity and engage in a thorough informed-consent process before prescribing BPC-157 compounded preparations.

Controlled Substance Status in Washington

BPC-157 is not scheduled under the DEA's Controlled Substances Act, and Washington's Uniform Controlled Substances Act (RCW 69.50) does not include it. [5] This means possession of BPC-157 for personal use is not a criminal offense under state drug law, but that does not make it legal for sale or clinical use without appropriate regulatory compliance.

The Science Gap That Drives Regulatory Hesitation

Understanding why regulators are cautious requires a brief look at the clinical evidence base. Or, more accurately, the absence of one.

Animal Data vs. Human Trials

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. A substantial body of rodent research has examined its effects on wound healing, gut mucosal protection, tendon repair, and neurological recovery. [6] One frequently cited rat study found that BPC-157 accelerated Achilles tendon-to-bone healing, showing statistically significant differences at 4 weeks compared with saline controls (P<0.01). [7]

The problem: rodent pharmacology does not reliably predict human outcomes. As the FDA's own guidance on 503A bulk substances notes, animal studies alone are insufficient to establish safety and effectiveness for human therapeutic use. [3] As of mid-2024, no completed Phase II or Phase III randomized controlled trial of BPC-157 in humans has been published in a peer-reviewed journal indexed on PubMed. ClinicalTrials.gov lists a small number of early-phase studies, but none have published efficacy results.

What the Research Record Does and Does Not Show

Rodent studies suggest BPC-157 may accelerate soft-tissue healing and may reduce gastric ulcer size by upregulating growth hormone receptor expression in fibroblasts. [8] Human pharmacokinetic data, therapeutic dose ranges, and long-term safety profiles are, as of this writing, essentially absent from the published literature.

The American Society of Health-System Pharmacists (ASHP) and the FDA have both noted that the lack of adequate clinical trial data is a primary reason peptides like BPC-157 receive Category 2 designations rather than approval or listing on the 503A bulks-approved list. [3]

How Washington Residents Currently Access BPC-157

Access pathways in Washington fall into three rough categories, each carrying different legal and safety profiles.

Pathway 1: Prescription from a Licensed Clinician, Filled at a 503A Compounding Pharmacy

A Washington-licensed physician, naturopathic doctor (ND), or nurse practitioner (NP) with prescriptive authority can write a prescription for BPC-157 as a compounded preparation. The prescription must be for an individual patient, based on a documented clinical rationale. A licensed 503A compounding pharmacy, either in-state or in another state that ships to Washington, can then prepare and dispense it.

This is the most legally defensible pathway currently available, though it still carries the risk that a future final FDA adverse determination could make the compound unavailable.

Pathway 2: Research Protocols

Universities and research institutions in Washington can use BPC-157 under IRB-approved animal or human research protocols. Human studies require both IRB approval and an Investigational New Drug (IND) application submitted to the FDA. [9] This pathway is not available to individual patients outside of an approved trial.

Pathway 3: Online "Research Chemical" Vendors

Numerous websites sell BPC-157 labeled "for research use only, not for human consumption." Purchasing from these vendors for self-administration falls outside any legal protective framework. The FDA has warned that products sold as research chemicals may be mislabeled, contaminated, or incorrectly dosed. [1] Injection of a non-sterile, non-pharmacy-grade peptide carries serious infection risk, including bacteremia and abscess formation.

The HealthRX clinical team uses the following three-question framework when evaluating a peptide request from a Washington patient: (1) Is there a Category 1 FDA-listed or approved alternative that addresses the same clinical indication? (2) Can the prescriber document a specific, individualized clinical rationale supported by at least animal-model or preliminary human data? (3) Is the compounding pharmacy 503A-registered, PCAB-accredited, and willing to provide a Certificate of Analysis for the batch? If any answer is "no," the prescription should not proceed under current HealthRX policy.

Telehealth and BPC-157 in Washington

Washington participates in the Interstate Medical Licensure Compact (IMLC), which allows licensed physicians from other states to obtain expedited Washington licensure. [10] A telehealth provider based in another state prescribing BPC-157 to a Washington resident must hold an active Washington license or registration. The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. 829) requires at least one in-person medical evaluation before prescribing controlled substances via telemedicine, but BPC-157 is not a controlled substance, so that specific restriction does not apply. Washington's telehealth parity laws (RCW 48.43.735) do require that telehealth services meet the same standard of care as in-person services.

What This Means for HealthRX Patients in Washington

A HealthRX clinician licensed in Washington can evaluate a patient via telehealth, document a clinical rationale, and submit a prescription for compounded BPC-157 to a 503A-registered pharmacy. The prescription must include the specific dosage form (e.g., 250 mcg per dose sterile injectable solution or oral capsule), concentration, quantity, and directions for use. Patients should receive written informed consent documentation that explains the investigational nature of the compound, the absence of FDA approval, and the current Category 2 regulatory status.

Risks of Operating Outside the Legal Framework

Self-sourcing BPC-157 from unregulated vendors creates risks that go beyond legal exposure.

Product Quality

Third-party testing of peptides sold as research chemicals has found purity rates ranging from below 70% to above 99% across different vendors, with no reliable way for a consumer to verify quality without independent laboratory analysis. A 2022 analysis published in connection with peptide quality discussions noted that endotoxin contamination in poorly manufactured injectable peptides could trigger systemic inflammatory responses. [11]

Prescriber Liability

A Washington physician who recommends or endorses a specific unregulated online vendor could face Medical Quality Assurance Commission sanctions and potential civil liability if a patient is harmed.

Legal Possession vs. Legal Sale

Possessing BPC-157 purchased online is not a criminal act under current Washington law. Selling it for human use without a pharmacy license, however, violates both state pharmacy law and the FD&C Act's prohibition on dispensing prescription drugs without a valid prescription.

Monitoring FDA Rulemaking: What to Watch

The FDA's 503A bulks rulemaking process moves through defined stages: nomination, Category 1 or 2 designation, public comment period, and then either addition to the approved list or a final adverse determination. [2] Once a final adverse determination is published in the Federal Register, 503A compounding pharmacies must stop compounding that substance within a specified wind-down period, typically 90 to 180 days.

Clinicians and patients in Washington who currently use compounded BPC-157 should monitor the FDA's 503A Bulk Substances page for status changes. The FDA's most recent 503A bulk substances update noted that substances in Category 2 "have been evaluated and found to present concerns," but that a final rule has not been issued. [3]

The FDA's page for 503A bulk substance nominations is available at: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca [3]

Naturopathic Doctors and BPC-157 in Washington

Washington is one of a small number of states that license naturopathic physicians (NDs) with prescriptive authority under RCW 18.36A. Licensed NDs in Washington can prescribe legend drugs and, in some cases, compounded preparations within their scope of practice. Whether BPC-157 falls within an ND's scope depends on both the prescribing authority granted by state law and the individual ND's training and documentation practices. An ND considering prescribing compounded BPC-157 should consult with the Washington State Department of Health and confirm that the compounding pharmacy's 503A registration is current.

Veterinary Use in Washington

BPC-157 is sold openly by research-chemical suppliers for veterinary research. Washington's veterinary practice act (RCW 18.92) and the state Veterinary Board of Governors regulate veterinary drug use. A licensed veterinarian in Washington can prescribe compounded preparations for individual animal patients under a valid veterinarian-client-patient relationship (VCPR). The FDA's Center for Veterinary Medicine (CVM) regulates veterinary drugs separately from CDER, and BPC-157 has not received a NADA (New Animal Drug Application) approval. Compounding for individual animal patients under a VCPR follows similar 503A logic applied to veterinary compounding under AMDUCA (the Animal Medicinal Drug Use Clarification Act). [12]

What Clinicians Should Document

Any Washington clinician prescribing compounded BPC-157 should maintain a medical record that includes:

• A specific diagnosis or clinical indication with supporting examination findings or objective data
• A summary of why no FDA-approved alternative adequately addresses the patient's condition
• Documentation that the patient received and understood an informed consent discussion covering the compound's investigational status
• The name, 503A registration number, and PCAB accreditation status of the dispensing pharmacy
• A plan for clinical monitoring, including follow-up intervals and outcome measures

The Endocrine Society's 2023 clinical practice guideline on peptide and hormone therapies, while not specifically addressing BPC-157, states that clinicians prescribing compounded preparations "should ensure that the clinical rationale is documented and that patients are informed of the unapproved status of the compound." [13]